R&D Logic's Customers Meet Over the Web.
August 2003 — In an effort to better serve our customers, R&D Logic organizes quarterly webinars to discuss topics of common interest. The first such webinars are being held this month to present new features of the latest product release. Watch for announcements of future topics!
J2EE Platform.
August 2003 — R&D Logic has adopted J2EE as its new strategic technical platform. New products under development are switched to the new technology. R&D Logic is also pleased to announce the hiring of Mr. Wayne Kidd to spearhead the implementation of the J2EE architecture and platform. Mr. Kidd, well known by the Java community, brings a wealth of technical expertise and product development experience to our efforts.
R&D Manage Release 2.2.
December 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded with additional currency exchange, planning and reporting capabilities.
NPS Pharmaceuticals has selected the R&D Manage™ solution to support budgeting and forecasting of their world wide expenses.
August 2002 — NPS Pharmaceuticals, Inc. located in Salt Lake City, Utah has subscribed to R&D Logic software solution and services. NPS Pharmaceuticals was founded in 1986 and is engaged in the discovery and development of novel, small molecule drugs and recombinant peptides that address a variety of important diseases. With operations in both US and Canada, NPSP will start using the R&D Manage software by developing a detailed global budget across the various organizations.
Discovery Partners International has selected the R&D Manage™ solution to plan and track their consolidated financials.
August 2002 — Discovery Partners International, Inc. located in San Diego, California has subscribed to R&D Logic software solution and services. Discovery Partners has become a leader in drug discovery collaborations by offering integrated services and products that span the drug discovery continuum including target characterization, high throughput screening, lead generation, lead optimization, high throughput synthesis automation, and gene expression analysis. With operations in both US and Europe, DPI will start using the R&D Manage software by developing a detailed global budget for the entire corporation.
Guilford Pharamceuticals has selected R&D Manage™ solution to support their objective driven financial planning and tracking process.
July 2002 — Guilford Pharmaceuticals, Inc. located in Baltimore, Maryland has subscribed to R&D Logic software solution and services. With implementation efforts already under way, we are looking forward to integrating the R&D Manage software within a unified platform for budgeting and forecasting of the Guilford financials.
Novacea has opted for the R&D Manage™ solution to plan and track their financials.
July 2002 — Novacea, Inc. located in South San Francisco, California has subscribed to R&D Logic software solution and services. Novacea is a rapidly growing drug development company that has the exclusive worldwide rights to the Oregon Health & Science University (OHSU) technology for dose and a method of use of calcitriol and its analogs, potentially providing a major breakthrough in the treatment of cancer. R&D Manage will be first used to create a long range plan of the Company financials, with an emphasis on clinical trial costs.
CellGate has selected R&D Manage™ to support budgeting and forecasting monthly reporting activities for their rapidly expanding operations.
April 2002 — CellGate, Inc. located in Sunnyvale, California has subscribed to R&D Logic software solution and services. CellGate is a pioneer in the application and development of transporter molecules to deliver novel medicines into cells and through tissues.
R&D Manage Release 2.1.7.
January 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded with additional reporting capabilities.
R&D Manage Release 2.2.1.
January 2002 — The newest release of R&D Manage product has been rolled out to all current customers. The software functionality has been expanded with additional direct and indirect project costing capabilities.
R&D Manage Release 2.1.
January 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded to include budgeting based on standard rates; existing functions have been improved and enhanced as well.
Neurogenetics acquires global license for using R&D Manage.
October 2001 — NEUROGENETICS, Inc. has subscribed to R&D Manage software and services. Neurogenetics is a San Diego-based emerging biopharmaceutical company focused on the development of therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, including Parkinson's disease (PD), Huntington’s disease (HD), stroke, amyotrophic lateral sclerosis (ALS), epilepsy and chronic pain.
PHARMOS Corporation has subscribed to R&D Manage software and services.
October 2001 — PHARMOS Corporation has subscribed to R&D Manage software and services. Additionally, R&D Manage will support consolidation between the Israel and US divisions. Pharmos Corporation is a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central and peripheral nervous systems, and ophthalmologic, cardiovascular and inflammation-related indications.
Neurogen (Connecticut) and Pharmos (New Jersey) have selected R&D Manage to support their budgeting and forecasting monthly reporting activities.
October 2001 — NEUROGEN Corporation has acquired a global license for using R&D Manage software and services. Neurogen is a leader in both the discovery and development of new drug candidates and in the development and integration of new drug discovery technologies, most notably its AIDD (Accelerated Intelligent Drug Discovery) system.
HYSEQ and ZYOMYX have selected R&D Manage™ to plan and track their operating expenses.
July 2001 — Hyseq, Inc. and Zyomyx have recently subscribed to R&D Manage software and services. Hyseq, located in Sunnyvale, California, applies its genomics platform to find and develop biopharmaceuticals products. Zyomyx, located in Hayward, California, is developing a new generation of biochips which will enable miniaturized, ultrahigh-throughput protein analyses to bridge the technology gap in the discovery process for the biological and life sciences industry.
10 biotech and pharmaceutical companies are now using our solution for budgeting and forecasting, planning and tracking.
June 2001 — NeoTherapeutics, Inc. and Metabolex, Inc. have recently joined our user community. NeoTherapeutics, located in Irvine, California, is a development-stage biopharmaceutical company engaged in the discovery and advancement of novel therapeutic agents intended to treat neurological and psychiatric diseases and conditions. Metabolex discovers and develops new drugs for type 2 diabetes and brings to market novel drugs with distinct and complementary modes of action, to address the full range of defects underlying diabetes. Both companies will be using R&D Manage on a subscription mode and will first use the system to create their 2002 budgets.
Valentis, Inc. has subscribed to R&D Manage.
March 2001 — Valentis, Inc, is taking the discoveries of genomics research and applying proprietary delivery systems to create therapeutics with improved safety, efficacy or dosing convenience. Valentis has what is believed to be the broadest array of technologies and intellectual property for the delivery of biopharmaceuticals in the industry. R&D Manage will be integrated with Platinum and the local time reporting system. The company has centers in three locations: The Woodlands, Texas, which houses the team focused on preclinical Research & Development; London, England, where PolyMASC operates as a wholly-owned subsidiary and focuses on polymer-based delivery; and Burlingame, California, which is the company headquarters as well as the center for manufacturing and clinical development. R&D Manage will be rolled out to the US locations in April 2001.
Sunesis and Cytokinetics Inc. have also joined our R&D Manage subscription community.
February 2001 — Sunesis Pharmaceuticals is applying a revolutionary new approach to drug discovery that is based on a novel chemical methodology combined with critical insights into the nature of molecular recognition between natural macromolecules and their substrates or ligands. Sunesis will be using R&D Manage™ and the electronic integration with Quick Books. Cytokinetics Inc. is focused on the complementary missions of drug discovery and the commercialization of novel cellular bioinformatics technologies. We are excited to integrate R&D Manage™ with the General Ledger of Microsoft Dynamics accounting system.
Intrabiotics has subscribed to R&D Manage.
February 2001 — Intrabiotics Pharmaceuticals Inc, is a biopharmaceutical company developing novel antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases, including those related to the phenomenon of multi-drug resistant microbes and the infectious complications of neutropenia. R&D Manage™ will be integrated with MAS90 and local time reporting system.
BioSpace.com has subscribed to R&D Manage.
November 2000 — BioSpace.com, Inc. is the most heavily trafficked business-to-business life sciences site on the Internet today. The company has selected R&D Manage as the tool to budget and forecast their P&L by project and by organization.